ZA200405437B - Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for the prevention or treatment of pathogenic conditions. - Google Patents
Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for the prevention or treatment of pathogenic conditions.Info
- Publication number
- ZA200405437B ZA200405437B ZA200405437A ZA200405437A ZA200405437B ZA 200405437 B ZA200405437 B ZA 200405437B ZA 200405437 A ZA200405437 A ZA 200405437A ZA 200405437 A ZA200405437 A ZA 200405437A ZA 200405437 B ZA200405437 B ZA 200405437B
- Authority
- ZA
- South Africa
- Prior art keywords
- alpha
- prevention
- treatment
- receptor antagonist
- combination therapy
- Prior art date
Links
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 title 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 230000001717 pathogenic effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35380102P | 2002-01-30 | 2002-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200405437B true ZA200405437B (en) | 2005-07-08 |
Family
ID=27663255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200405437A ZA200405437B (en) | 2002-01-30 | 2004-07-08 | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for the prevention or treatment of pathogenic conditions. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20030199483A1 (enExample) |
| EP (1) | EP1469862A2 (enExample) |
| JP (1) | JP2005519918A (enExample) |
| KR (1) | KR20040096540A (enExample) |
| CN (1) | CN1625404A (enExample) |
| BR (1) | BR0307336A (enExample) |
| CA (1) | CA2474845A1 (enExample) |
| MX (1) | MXPA04007472A (enExample) |
| PL (1) | PL371437A1 (enExample) |
| WO (1) | WO2003063846A2 (enExample) |
| ZA (1) | ZA200405437B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381163C (zh) * | 2006-08-29 | 2008-04-16 | 陈俊云 | 一种含利美尼定的药物 |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| WO2016141182A1 (en) | 2015-03-03 | 2016-09-09 | Yee Richard W | Compositions and methods for treating ocular diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| WO2001087284A2 (en) * | 2000-05-11 | 2001-11-22 | Pharmacia Corporation | Aldosterone antagonist composition for release during aldosterone acrophase |
| US20040235809A1 (en) * | 2000-07-27 | 2004-11-25 | Alexander John C | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure |
| WO2003049745A1 (en) * | 2001-12-12 | 2003-06-19 | Pharmacia Corporation | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
-
2003
- 2003-01-30 EP EP20030710786 patent/EP1469862A2/en not_active Withdrawn
- 2003-01-30 KR KR10-2004-7011714A patent/KR20040096540A/ko not_active Ceased
- 2003-01-30 MX MXPA04007472A patent/MXPA04007472A/es unknown
- 2003-01-30 BR BR0307336-0A patent/BR0307336A/pt not_active IP Right Cessation
- 2003-01-30 PL PL03371437A patent/PL371437A1/xx not_active Application Discontinuation
- 2003-01-30 US US10/354,653 patent/US20030199483A1/en not_active Abandoned
- 2003-01-30 CN CNA03802988XA patent/CN1625404A/zh active Pending
- 2003-01-30 WO PCT/US2003/002723 patent/WO2003063846A2/en not_active Ceased
- 2003-01-30 CA CA002474845A patent/CA2474845A1/en not_active Abandoned
- 2003-01-30 JP JP2003563540A patent/JP2005519918A/ja not_active Abandoned
-
2004
- 2004-07-08 ZA ZA200405437A patent/ZA200405437B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030199483A1 (en) | 2003-10-23 |
| CA2474845A1 (en) | 2003-08-07 |
| MXPA04007472A (es) | 2004-11-10 |
| WO2003063846A3 (en) | 2003-12-04 |
| BR0307336A (pt) | 2004-12-07 |
| JP2005519918A (ja) | 2005-07-07 |
| PL371437A1 (en) | 2005-06-13 |
| EP1469862A2 (en) | 2004-10-27 |
| WO2003063846A2 (en) | 2003-08-07 |
| KR20040096540A (ko) | 2004-11-16 |
| CN1625404A (zh) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200410011B (en) | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | |
| ZA200500323B (en) | Use of lkb kinase inhibitors for the treatment of pain. | |
| PL1656372T3 (pl) | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym | |
| WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
| WO2006047716A3 (en) | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease | |
| PL369527A1 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
| WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| MY137620A (en) | Therapeutic treatment | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| WO2002017895A3 (en) | Use of an aldosterone receptor antagonist to improve cognitive function | |
| AU2003290059A8 (en) | Use of cd137 antagonists for the treatment of tumors | |
| IL175974A (en) | Radiation protection plugins | |
| ZA200003236B (en) | Combination therapy for the treatment of migraine. | |
| AU1604001A (en) | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects | |
| MXPA03006776A (es) | Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca. | |
| ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
| EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
| UA85187C2 (en) | 2-aminobenzoyl derivatives | |
| PL371437A1 (en) | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions | |
| PT1534296E (pt) | UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA | |
| WO2006053014A3 (en) | Selective inhibition of rock1 in cardiac therapy | |
| ZA200002338B (en) | Combination therapy for the treatment of migraine. | |
| IL136962A0 (en) | Combination therapy for the treatment of migraine | |
| MXPA03009506A (es) | USO DE COMPUESTOS ELIMINADORES DE RADICALES PARA EL TRATAMIENTO Y PREVENCIoN DE TRASTORNOS DE LA MICRO-CIRCULACION DEPENDIENTES DE NO. | |
| ZA200002343B (en) | Combination therapy for the treatment of migraine. |